Current Clinical Trials

Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sub-Investigator(s):
Sponsor: CALGB
Details (Identifier #): NCT00499330
Title: CALGB 140503 - A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (<2 cm) Peripheral Non-Small Cell Lung Cancer
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lash MD, Bradley
Sponsor: MacroGenics
Details (Identifier #): NCT02492711
Title: MacroGenics SOPHIA, CP-MGAH22-04, A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lash MD, Bradley
Sponsor: Celldex
Details (Identifier #): NCT01997333
Title: CDX011-04, A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: Mirati
Details (Identifier #): NCT02544633
Title: 265-109, A Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor
Department: Gastroenterology
Diagnosis: Gastrointestinal - Miscellaneous
Principal Investigator: McDonald M.D., Thomas
Sponsor: Janssen
Details (Identifier #): none
Title: Limited access protocol for the use of oral cisapride in the treatment of refractory gastroesophageal reflux disease and other gastrointestinal motility disorders. CIS-USA-154
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator:
Sub-Investigator(s):
Sponsor: NCI
Details (Identifier #): NCT02502266
Title: Protocol NRG-GY005,A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sub-Investigator(s):
Sponsor: ECOG
Details (Identifier #): NCT01169337
Title: E3A06: Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
Department: Cardiology
Diagnosis: Cardiac - Arrhythmia
Principal Investigator: Deshmukh MD, Pramod
Sponsor: St. Jude Medical
Details (Identifier #): NCT02548455
Title: A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an Investigational Device Exemption (IDE) Study
Department: Oncology
Diagnosis: Melanoma
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Details (Identifier #): NCT02224781
Title: EA6134, A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
Department: Gastroenterology
Diagnosis: Gastrointestinal - Crohn's
Principal Investigator: Georgetson MD, FACG, Michael
Sponsor: Salix
Details (Identifier #): NCT02240121
Title: A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional Study to Assess the Efficacy and Safety of Rifaximin Delayed Release Tablets for the Induction and Maintenance of Remission in Subjects with Active Moderate Crohn's Disease (RECD3125)